Ultragenyx Pharmaceutical RARE Cost of Sales
Cost of Sales at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept rare:CostOfSales.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's cost of sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's cost of sales?
- Ultragenyx Pharmaceutical (RARE) reported cost of sales of $30M in Q1 2026.
- How has Ultragenyx Pharmaceutical's cost of sales changed year-over-year?
- Ultragenyx Pharmaceutical's cost of sales increased by 3.4% year-over-year, from $29M to $30M.
- What is the long-term trend for Ultragenyx Pharmaceutical's cost of sales?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's cost of sales has grown at a 61.7% compound annual growth rate (CAGR), from $16.01M to $109.34M.
- What does cost of sales mean?
- This metric represents the direct costs attributable to the production and delivery of goods or services sold by the company. It typically includes raw materials, direct labor, and manufacturing overhead required to generate revenue. Monitoring this figure helps investors assess the company's gross margin efficiency and direct production cost management.